Mohammed Harb

1.2k total citations
9 papers, 194 citations indexed

About

Mohammed Harb is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Mohammed Harb has authored 9 papers receiving a total of 194 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Cancer Research and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Mohammed Harb's work include Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Mohammed Harb is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Mohammed Harb collaborates with scholars based in Canada, United States and France. Mohammed Harb's co-authors include Jay S. Wunder, David Swanson, Yun‐Shao Sung, Victor E. Reuter, Cristina R. Antonescu, Brendan C. Dickson, Marc K. Rosenblum, Petr Kavan, Derek J. Jonker and Nathalie Aucoin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The American Journal of Surgical Pathology.

In The Last Decade

Mohammed Harb

9 papers receiving 192 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mohammed Harb Canada	5	126	72	46	38	27	9	194
Michal Kubiak United States	5	114 0.9×	50 0.7×	47 1.0×	18 0.5×	46 1.7×	10	197
Surita Dalal United Kingdom	6	48 0.4×	75 1.0×	70 1.5×	55 1.4×	35 1.3×	15	185
Aparna Pallavajjalla United States	7	55 0.4×	138 1.9×	116 2.5×	24 0.6×	33 1.2×	10	226
Vinay Gudena United States	6	102 0.8×	53 0.7×	40 0.9×	33 0.9×	9 0.3×	18	181
Waled Bahaj United States	9	53 0.4×	64 0.9×	30 0.7×	44 1.2×	84 3.1×	36	200
Christian Hosius Germany	7	95 0.8×	84 1.2×	54 1.2×	16 0.4×	59 2.2×	19	228
Bérengère Dadone‐Montaudié France	7	56 0.4×	39 0.5×	73 1.6×	14 0.4×	10 0.4×	23	146
H M Amin United States	6	45 0.4×	75 1.0×	29 0.6×	48 1.3×	23 0.9×	6	331
Katharina Leonards Switzerland	4	84 0.7×	44 0.6×	68 1.5×	14 0.4×	17 0.6×	8	148
Walter Lindemann Germany	5	126 1.0×	25 0.3×	45 1.0×	64 1.7×	16 0.6×	5	189

Countries citing papers authored by Mohammed Harb

Since Specialization

Citations

This map shows the geographic impact of Mohammed Harb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Harb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Harb more than expected).

Fields of papers citing papers by Mohammed Harb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Harb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Harb. The network helps show where Mohammed Harb may publish in the future.

Co-authorship network of co-authors of Mohammed Harb

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed Harb. A scholar is included among the top collaborators of Mohammed Harb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed Harb. Mohammed Harb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Harb, Mohammed, et al.. (2025). Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis. Diagnostic Pathology. 20(1). 6–6. 1 indexed citations

Loree, Jonathan M., Derek J. Jonker, Hagen F. Kennecke, et al.. (2023). Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.. Journal of Clinical Oncology. 41(4_suppl). 183–183. 1 indexed citations

Chen, Eric Xueyu, Jonathan M. Loree, Dongsheng Tu, et al.. (2022). Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.. Journal of Clinical Oncology. 40(16_suppl). 3600–3600. 1 indexed citations

Renouf, Daniel J., Jonathan M. Loree, Jennifer J. Knox, et al.. (2021). Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 39(3_suppl). 411–411. 7 indexed citations

Renouf, Daniel J., Jonathan M. Loree, Jennifer J. Knox, et al.. (2021). Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 39(15_suppl). 4135–4135. 3 indexed citations

Knox, Jennifer J., Petr Kavan, Derek J. Jonker, et al.. (2020). LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). Annals of Oncology. 31. S1195–S1195. 33 indexed citations

Chen, Eric Xueyu, Derek J. Jonker, Hagen F. Kennecke, et al.. (2019). CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).. Journal of Clinical Oncology. 37(4_suppl). 481–481. 37 indexed citations

Chen, Eric Xueyu, Derek J. Jonker, Jonathan M. Loree, et al.. (2019). CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).. Journal of Clinical Oncology. 37(15_suppl). 3512–3512. 17 indexed citations

Dickson, Brendan C., Yun‐Shao Sung, Marc K. Rosenblum, et al.. (2018). NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. The American Journal of Surgical Pathology. 42(5). 636–645. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact